CESTAT upholds SPARC’s ₹2,751 lakh CENVAT credit refund
As filed · Sun Pharma Advanced Research Company Limited has informed the Exchange about update on Litigation.
RegulatoryImprovingMinormateriality 58 out of 100
What happened
FactThe Customs, Excise & Service Tax Appellate Tribunal, Mumbai upheld the 27 April 2018 Order-in-Appeal in favour of Sun Pharma Advanced Research Company. The tribunal confirmed the company’s entitlement to a refund of accumulated CENVAT credit of ₹2,751 lakhs, along with consequential interest where applicable, and dismissed the Revenue’s appeal.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
Scale
- 1.5% of FY26 revenue
₹27.51 Cr stated in the filing against ₹1,879.17 Cr revenue (FY26, standalone)
Source: financial_facts · exchange_table
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
Evidence
How CapitSignal classified this
- Reasoning:
- The decision resolves the disclosed litigation in the company’s favour and confirms its entitlement to the stated refund, with consequential interest where applicable.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%